Basiliximab induced non-cardiogenic pulmonary edema in two pediatric renal transplant recipients.
AffiliationDepartment of Nephrology, Children's University Hospital, Dublin, Ireland. firstname.lastname@example.org
Kidney Tubules, Distal
Recombinant Fusion Proteins
MetadataShow full item record
CitationBasiliximab induced non-cardiogenic pulmonary edema in two pediatric renal transplant recipients. 2009, 24 (11):2261-5 Pediatr. Nephrol.
JournalPediatric nephrology (Berlin, Germany)
AbstractWe report two cases of non-cardiogenic pulmonary edema as a complication of basiliximab induction therapy in young pediatric renal transplant patients identified following a retrospective review of all pediatric renal transplant cases performed in the National Paediatric Transplant Centre, Childrens University Hospital, Temple Street, Dublin, Ireland. Twenty-eight renal transplantations, of which five were living-related (LRD) and 23 were from deceased donors (DD), were performed in 28 children between 2003 and 2006. In six cases, transplantations were pre-emptive. Immunosuppression was induced pre-operatively using a combination of basiliximab, tacrolimus and methylprednisolone in all patients. Basiliximab induction was initiated 2 h prior to surgery in all cases and, in 26 patients, basiliximab was re-administered on post-operative day 4. Two patients, one LRD and one DD, aged 6 and 11 years, respectively, developed acute non-cardiogenic pulmonary edema within 36 h of surgery. Renal dysplasia was identified as the primary etiological factor for renal failure in both cases. Both children required assisted ventilation for between 4 and 6 days. While both grafts had primary function, the DD transplant patient subsequently developed acute tubular necrosis and was eventually lost within 3 weeks due to thrombotic microangiopathy and severe acute antibody-mediated rejection despite adequate immunosuppression. Non-cardiogenic pulmonary edema is a potentially devastating post-operative complication of basiliximab induction therapy in young pediatric patients following renal transplantation. Early recognition and appropriate supportive therapy is vital for patient and, where possible, graft survival.
- Non-cardiogenic pulmonary edema during basiliximab induction in three adolescent renal transplant patients.
- Authors: Bamgbola FO, Del Rio M, Kaskel FJ, Flynn JT
- Issue date: 2003 Aug
- Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal transplantation: a prospective, randomized study.
- Authors: Kandus A, Arnol M, Omahen K, Oblak M, Vidan-Jeras B, Kmetec A, Bren AF
- Issue date: 2010 Apr 27
- Basiliximab: a review of its use as induction therapy in renal transplantation.
- Authors: McKeage K, McCormack PL
- Issue date: 2010 Feb 1
- Effect of basiliximab on renal allograft rejection within 1 year after transplantation.
- Authors: Lee BM, Oh CK, Jin SH, Kim JH, Kim SJ, Kim H, Shin GT
- Issue date: 2006 Sep
- Comparison of single bolus ATG and Basiliximab as induction therapy in presensitized renal allograft recipients receiving tacrolimus-based immunosuppressive regimen.
- Authors: Yang SL, Wang D, Wu WZ, Lin WH, Xu TZ, Cai JQ, Tan JM
- Issue date: 2008 Jan